Aptalis Pharmaceutical Technologies said that its divestiture from Actavis plc to TPG, a global private investment firm, has been completed. The company also said that its new name is Adare Pharmaceuticals and John Fraher, who was president of Aptalis Pharmaceutical Technologies, has been named the chief executive officer. “For decades, we have solved complex formulation, manufacturing and commercialization challenges, which has resulted in transformational medicines that deliver value to all...